“…Covalent small molecules that target specific amino acid residues are powerful chemical tools that can reveal fundamental new protein function and identify lead candidates for accelerating drug discovery. − Indeed, led by advances across broad fields encompassing organic chemistry, chemical biology, cell biology, and bioinformatics, covalent therapeutics now constitute approximately 30% of enzyme-targeting FDA-approved drugs . In this context, activity-based protein profiling (ABPP), where chemical probes measure protein function rather than protein abundance, , has enabled new modalities for fragment-based drug discovery by applying small-molecule screening efforts in conjunction with chemoproteomics for target and site identification and characterization. − These technologies rely on residue-specific covalent warheads that can be used from proteins to proteomes, ,− yet the majority of reactive probe development to tackle this vast undruggable space has targeted cysteine , or lysine, ,,, with relatively limited expansion of this chemical toolbox to other nucleophilic residues like tyrosine and glutamate/aspartate. , …”